A Phase 2 Study to Evaluate the Efficacy and Safety of Cevostamab in Patients with Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

The primary objective of this study is to evaluate the efficacy of cevostamab in patients diagnosed with systemic lupus erythematosus, encompassing individuals with or without active lupus nephritis. Assessing the therapeutic impact of this agent is clinically significant for managing disease activity and potential organ involvement in this patient population. No secondary objectives were specified.

The study includes a total of 29 patients diagnosed with systemic lupus erythematosus, which may or may not include active lupus nephritis. The participant population consists of both females and males, including vulnerable individuals. Based on the provided age range codes, the subjects fall within specific developmental or age-defined categories. The sponsor did not provide additional information regarding selection processes, lifestyle considerations, or specific inclusion and exclusion criteria.

This Phase 3 clinical trial is designed to evaluate the effects of cevostamab in patients diagnosed with systemic lupus erythematosus, with or without active lupus nephritis. The study involves a sequence of clinical assessments beginning with a screening visit to determine eligibility. Subsequent follow-up visits are scheduled to monitor clinical responses and safety parameters, concluding with an end-of-study visit. Participation in the trial is expected to continue until the final assessment is completed. Conditions that may lead to early termination of an individual's involvement in the study are not specified.

Efficacy assessment for patients with Systemic Lupus Erythematosus will be conducted within the framework of this Phase 3 clinical trial. The specific parameters, measurement schedules, and assessment tools utilized to evaluate clinical outcomes have not been defined in the provided documentation.